What Adcytherix does

Adcytherix SAS is a clinical-stage biopharmaceutical company incorporated in Marseille, France in June 2024, developing next-generation antibody-drug conjugates (ADCs) for high-unmet-need cancers, with particular focus on tumors resistant to current-generation ADC therapies. The company's core technology is the proprietary ADCX-Engine platform, which integrates approved and clinically validated cancer drugs as payloads with optimized state-of-the-art linker architectures and precision antibody engineering to enable ADCs with fine-tuned conjugation parameters, broader therapeutic windows, and improved resistance profiles. Its lead product candidate, ADCX-020, combines a stable linker with an exatecan-derived topoisomerase I inhibitor payload and entered a Phase 1a/b dose-escalation and expansion trial in patients with advanced solid tumors, with the first patient dosed in March 2026.

The company is pre-revenue and pursues a B2B enterprise partnering model: it explicitly courts licensing and co-development deals with top-tier biotech and pharma companies as well as academic researchers across novel payload chemistry, target validation, and clinical translation, with future revenue expected from licensing milestones, co-development agreements, royalties, and ultimately the sale of proprietary ADC therapeutics upon regulatory approval. It operates with subsidiaries in the United States and the Netherlands alongside its Marseille headquarters, and is backed by a syndicate of top-tier life science investors including Pontifax, Bpifrance, Kurma Partners, Andera Partners, Angelini Ventures, Pureos Bioventures, RA Capital Management, DawnBiopharma (KKR), Surveyor Capital, and aMoon, having raised approximately €135 million in cumulative funding across a 2024 seed and 2025 Series A round.

Name

Adcytherix

Legal name

Adcytherix SAS

Website

https://adcytherix.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

11–50 employees

Short description

Adcytherix is a clinical-stage French biopharmaceutical company developing next-generation antibody-drug conjugates (ADCs) through its proprietary ADCX-Engine platform, targeting cancers resistant to current-generation ADCs and serving enterprise pharma and biotech partners via licensing and co-development deals.

Ownership category

akta.pro rank

Product category

Oncology Biopharmaceuticals

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE)

Keywords

• Antibody drug conjugates
• Oncology therapeutics
• ADC development
• Targeted cancer therapy
• Biopharmaceutical pipeline

Headquarters

HQ city

Marseille

HQ country

France

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Product revenue (future): Pre-revenue clinical-stage biopharma company. No commercial products yet. Future revenue expected from sale of proprietary ADC therapeutic products upon regulatory approval.
2. Licensing and co-development deals: The company is open to partnerships with top-level biotech and pharma companies and academic researchers for novel payload chemistry, target validation and clinical translation. Revenue anticipated from licensing deals, co-development agreements and milestone payments as products advance through clinical development.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Adcytherix is a clinical-stage biopharmaceutical company developing next-generation antibody-drug conjugates (ADCs) for cancer treatment. Its core work centers on the proprietary ADCX-Engine platform, which combines clinically validated targets with innovative payloads derived from approved cancer drugs, optimized linker architectures and precision antibody engineering. The lead candidate ADCX-020 is in a Phase 1 trial in patients with advanced solid tumors, designed to overcome resistance to current-generation ADCs and broaden the therapeutic window.

Product overview

Adcytherix is a clinical-stage biopharmaceutical company developing a portfolio of next-generation antibody-drug conjugates (ADCs) for treating high unmet need diseases, particularly cancer. The company's product strategy centers on two key offerings: (1) the ADCX-Engine, a proprietary technology platform enabling the development of differentiated ADCs using clinically validated payloads and advanced conjugation engineering; and (2) ADCX-020, the lead drug candidate currently in Phase 1 clinical development for advanced solid tumors. The company is advancing its pipeline to address resistance against current-generation ADCs and broaden the therapeutic window across multiple oncology indications.

Differentiator

Problem solved

Functional benefit

Products and services

• ADCX-Engine The ADCX-Engine is Adcytherix's proprietary ADC design platform that integrates approved and clinically validated cancer drugs as payloads with optimized, state-of-the-art linker architectures and precision antibody engineering. It enables rational design of highly selective ADCs with fine-tuned conjugation parameters that extend beyond conventional payload classes, enhance stability, overcome resistance, and improve safety while achieving deeper, more durable anti-tumor responses.
• ADCX-020 ADCX-020 is Adcytherix's lead ADC drug candidate incorporating a stable linker and an exatecan-derived topoisomerase I inhibitor payload. Designed to address key limitations of earlier ADC products through optimized molecular design to support an improved therapeutic index and broader applicability across multiple tumor types, it is being evaluated in a Phase 1 study in patients with advanced solid tumors.

Quantifiable outcome

• First patient dosed in Phase 1 trial within less than two years of company inception (March 2026)
• +1 more outcomes

Segments1 record

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• One BiosciencesminorStrategic or Co-development Partner · 1 January 2026One Biosciences received a PSCC BOOST grant from the Paris-Saclay Cancer Cluster to develop the first single-cell assay for ADC therapies in oncology, in collaboration with Adcytherix. The project combines Adcytherix's ADC development expertise with One Biosciences' AI-powered single-cell profiling technology to analyze tumor samples and identify cellular signatures associated with treatment response, supporting precision oncology.

Scale indicators4 records

Recent moves7 records

Expansion highlights7 records

Direct peers

• ADC Therapeutics: Commercial-stage ADC company with approved product Zynlonta and a pipeline of pyrrolobenzodiazepine-based ADCs for hematologic and solid tumors. Comparable as an ADC-focused oncology biotech with proprietary payload chemistry.
• Bolt Biotherapeutics: Clinical-stage oncology company developing immune-stimulating antibody-drug conjugates (ISACs). Comparable as a next-generation ADC biotech developing novel ADC mechanisms for solid tumors.
• Heidelberg Pharma: Germany-based clinical-stage ADC company leveraging proprietary amanitin payload chemistry (ATAC platform). Comparable as a European ADC platform company focusing on novel payload classes for cancer therapy.
• Pyxis Oncology: Clinical-stage oncology biotech developing ADC and antibody-based therapeutics for solid tumors. Comparable as an ADC-focused biotech pursuing novel antibody-drug conjugate designs in oncology.
• Tubulis: Germany-based clinical-stage biotech developing next-generation ADCs with proprietary payload and linker platforms (P5 conjugation, TOPi payloads). Highly comparable European ADC peer with similar platform-and-payload innovation strategy.
• Sutro Biopharma: Clinical-stage biotech with a cell-free protein synthesis platform developing ADCs and other biologics. Comparable as a platform-based ADC developer with lead programs in solid tumor oncology.
• Mersana Therapeutics: Clinical-stage ADC biotech developing next-generation antibody-drug conjugates with proprietary payload and linker platforms (e.g., Dolasynthen, Immunosynthen). Closely comparable as a platform-driven ADC company targeting solid tumors with novel conjugation chemistry.

Emerging players

• Mythic Therapeutics: Clinical-stage ADC biotech developing next-generation antibody-drug conjugates for solid tumors using proprietary technology. Comparable as an emerging player in novel ADC design.
• ProfoundBio: Clinical-stage ADC company developing next-generation antibody-drug conjugates for solid tumors, recently acquired by Genmab. Comparable as an emerging ADC peer with novel payload and linker approaches.

Broad incumbents

• Daiichi Sankyo: Global pharmaceutical company and ADC market leader through Enhertu (DXd ADC platform) jointly developed with AstraZeneca. Comparable as a broad incumbent that defines the competitive standard in the ADC space Adcytherix is targeting.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/adcytherix

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries2 records

Funding overview

Funding rounds2 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Adcytherix